论文部分内容阅读
１９９１年１月～１９９２年１月，用足叶乙甙和阿糖胞苷组成的ＥＡ方案治疗慢性粒细胞白血病慢性期患者１３例，取得较好效果，完全缓解８例，部分缓解５例，全部有效。ＥＡ方案能迅速使过高的外周血白细胞降至正常，降至≤１０×１０９／Ｌ平均需１０．３天，降至最低需１８．９天。对血红蛋白和血小板影响不大。在缩小肝脾方面亦显著。ＥＡ方案在改善细胞遗传学方面有较好疗效，Ｐｈ＋细胞率平均下降４４．６％。治疗中无出血、血拴形成倾向，未见心、肝、肾毒性。该方案近期疗效好，远期疗效和巩固治疗方法有待观察。
From January 1991 to January 1992, EA regimen consisting of etoposide and cytarabine was used to treat 13 chronic patients with chronic myeloid leukemia, and achieved good results, with complete remission in 8 cases, partial remission in 5 cases, All valid. The EA regimen quickly lowers excessively high levels of peripheral white blood cells to normal, down to an average of 10.3 days for ≤10 × 109 cells / L, and a minimum of 18.9 days for a minimum of 10 days. Little effect on hemoglobin and platelets. In reducing the liver and spleen are also significant. EA program has a good effect in improving cytogenetics, Ph + cell rate decreased by an average of 44.6%. No bleeding in the treatment, the formation of blood tethered tendency, no heart, liver and kidney toxicity. The recent efficacy of the program, long-term efficacy and consolidation treatment remains to be seen.